9d
Zacks Investment Research on MSNAmgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should KnowAmgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...
Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...
Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...
Explore more
The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...
In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical ...
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Let's discuss whether Amgen or Merck stock offers better value. The price-to-earnings (P/E) ratio is a financial metric that divides a stock's price by its earnings per share (EPS) as a quick way ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results